Robert J. Dempsey

Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Shire utilizing biotech approach to meet unmet ophthalmic needsShire, which built its experience in biotech agents, is taking a biotech approach to meeting unmet needs in both the anterior and poster segments of ophthalmology.